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Background and Purpose: cGMP underpins the bioactivity of NO and natriuretic
peptides and is key to cardiovascular homeostasis. cGMP-driven responses are termi-
nated primarily by PDEs, but cellular efflux via multidrug resistance proteins (MRPs)
might contribute. Herein, the effect of pharmacological blockade of MRPs on cGMP
signalling in the heart and vasculature was investigated in vitro and in vivo.
Experimental Approach: Proliferation of human coronary artery smooth muscle cells
(hCASMCs), vasorelaxation of murine aorta and reductions in mean arterial BP
(MABP) in response to NO donors or natriuretic peptides were determined in the
absence and presence of the MRP inhibitor MK571. The ability of MRP inhibition to
reverse morphological and contractile deficits in a murine model of pressure
overload-induced heart failure was also explored.
Key Results: MK571 attenuated hCASMC growth and enhanced the anti-
proliferative effects of NO and atrial natriuretic peptide (ANP). MRP blockade caused
concentration-dependent relaxations of murine aorta and augmented responses to
ANP (and to a lesser extent NO). MK571 did not decrease MABP per se but
enhanced the hypotensive actions of ANP and improved structural and functional
indices of disease severity in experimental heart failure. These beneficial actions of
MRP inhibition were associated with a greater intracellular:extracellular cGMP ratio
in vitro and in vivo.
Conclusions and Implications: MRP blockade promotes the cardiovascular functions
of natriuretic peptides in vitro and in vivo, with more modest effects on NO. MRP
inhibition may have therapeutic utility in cardiovascular diseases triggered by
dysfunctional cGMP signalling, particularly those associated with altered natriuretic
peptide bioactivity.
Abbreviations: ABC, ATP-binding cassette; ANP, atrial natriuretic peptide; Deta-NO, diethylenetriamine-NONOate; hCASMC, human coronary artery smooth muscle cell; HR, heart rate; KO,
knockout; LV, left ventricle; MABP, mean arterial BP; MK571, 5-(3-(2-(7-chloroquinolin-2-yl)ethenyl)phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoic acid; MRP, multidrug resistance protein;
ODQ, 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one; SNP, sodium nitroprusside; Sper-NO, spermine-NONOate; VASP, vasodilator stimulated phosphoprotein; VSMC, vascular smooth muscle
cell.
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1 | INTRODUCTION
cGMP is a common intracellular second messenger responsible for
conveying many of the cardiovascular actions of NO and natriuretic
peptides (Kuhn, 2016; Papapetropoulos et al., 2015). Generated by
NO-sensitive (GC-1 and GC-2) and natriuretic peptide-sensitive (GC-
A and GC-B) GCs, this ubiquitous molecule possesses a number of
cytoprotective roles including vasodilator, anti-leukocyte, anti-plate-
let, anti-fibrotic and anti-hypertrophic actions (Preedy et al., 2020).
Cellular levels of cGMP are dynamically regulated in a spatial and
temporal fashion, the result of a balance between GC-mediated
formation and enzymatic hydrolysis by PDEs. Indeed, targeting of
these synthetic (e.g. sGC stimulators and NO donors) and degradative
(e.g. PDE5 inhibitors) pathways has proven clinically effective in a
number of cardiovascular diseases including heart failure and
pulmonary arterial hypertension (Galie et al., 2005; Ghofrani
et al., 2013; Roberts et al., 1992). The discrete localisation of these
synthetic and degradatory enzymes enables compartmentalisation of
cGMP-regulated processes to distinct cellular localities. This phenom-
enon has been established largely in cardiomyocytes and vascular
smooth muscle cells (VSMCs) through the utilisation of cGMP-specific
FRET sensors (Calamera et al., 2019; Russwurm & Koesling, 2018;
Sinha et al., 2013; Subramanian et al., 2018; Thunemann et al., 2013)
but also by functional pharmacological assessment of selelective GC
ligands (i.e. NO vs. natriuretic peptides) and PDE inhibitors (Baliga
et al., 2018; Bubb et al., 2014; Kokkonen & Kass, 2017; Moltzau
et al., 2014; Zhao et al., 1999). Intriguingly, these cutting-edge
approaches have also given rise to the possibility that cellular efflux
plays a further, active role in terminating the biological actions
of cGMP (Krawutschke et al., 2015) (and also in intercellular
transfer, Menges et al., 2019). Indeed, appreciation of the
compartmentalisation and cellular efflux of sibling cAMP in vitro and
in vivo is comparatively well established (Sassi et al., 2008; Sinha
et al., 2013; Vettel et al., 2017; Zoccarato et al., 2015).
Cellular efflux of cyclic nucleotides is thought to depend on the
action of multidrug resistance proteins (MRPs) (Jedlitschky
et al., 2000; Schuetz et al., 1999). These energy-dependent,
transmembrane transporters belong to the superfamily of large
adenosine-50-triphosphate (ATP)-binding cassette (ABC) proteins,
which include 10 MRPs, two sulfonylurea receptors and the cystic
fibrosis transmembrane-conductance regulator (Dean et al., 2001;
Deeley et al., 2006). ABC transporters are unidirectional (i.e. transport
from the intracellular to the extracellular space) and ATP dependent
and have a hugely diverse substrate profile that includes xenobiotics
and therapeutic agents (Dean et al., 2001; Deeley et al., 2006). Two
MRP isozymes are thought to primarily underpin efflux of cGMP and
cAMP; MRP4 (ABCC4) and MRP5 (ABCC5), along with a modest
contribution from MRP8 (ABCC11; Slot et al., 2011). Both trans-
porters are widely expressed in the cardiovascular system, being
found in VSMCs, endothelial cells and cardiomyocytes (Cheepala
et al., 2013; Slot et al., 2011), and are inhibited by MK571. Indeed,
this pharmacological tool, alongside MRP4/ and MRP5/ mice, has
been used to establish cellular cGMP efflux as a key mechanism for
regulation of cGMP signalling. For example, MRP4 expression is sig-
nificantly increased in both VSMCs and endothelial cells at the mRNA
and protein levels in lungs from patients with pulmonary hypertension
(PH) compared with controls and is the same in a murine model of pul-
monary hypertension. In accord, administration of MK571 or MRP4
(Abcc4) gene deletion causes resistance to hypoxia-induced
pulmonary hypertension (Hara et al., 2011). Notably, the effect of
MRP inhibition is accentuated in the presence of sildenafil, suggesting
that in the absence of PDE degradation, MRP activity is significantly
elevated and takes on a more substantial role in cGMP inactivation.
Indeed, genetic deletion of MRP4 leads to significantly increased
heart weight, cardiomyocyte size and left ventricular (LV) wall
thickness with a concomitant increase in cardiac atrial natriuretic
peptide (ANP; Nppa) gene expression (Sassi et al., 2012). Such mice
What is already known
• Cyclic nucleotide compartmentalisation spatially and tem-
porally constrains cGMP and cAMP signalling.
• cGMP and cAMP cellular efflux may represent an impor-
tant mechanism for regulating cyclic nucleotide signalling.
What this study adds
• Pharmacological inhibition of multidrug resistance pro-
teins (MRPs) promotes cGMP signalling in the heart and
vasculature.
• cGMP production by membrane-spanning GCs, triggered
by natriuretic peptides, is governed preferentially by
MRP activity.
What is the clinical significance
• Augmenting cGMP signalling is established to be benefi-
cial in a number of cardiovascular diseases.
• MRPs inhibition might represent alone or adjunct therapy
to optimise the therapeutic benefits of cGMP.
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also exhibit an extended bleeding time demonstrating that MRP4
promotes platelet aggregation by decreasing intracellular cAMP and
cGMP (Borgognone & Pulcinelli, 2012). Interestingly, MRP5
expressio is increased in the hearts of patients suffering from
ischaemic cardiomyopathy and dilated cardiomyopathy, suggesting
that this MRP isozymes may contribute to the pathology and that
inhibition of MRP5 might be an attractive target to increase beneficial
intracellular cyclic nucleotide concentrations (Dazert et al., 2003) Yet,
MRP5/ mice do not have an overt phenotype, a finding that is also
true for MRP4//MRP5/ animals (Borst et al., 2007). This is at
odds with the adverse cardiovascular phenotype in MRP4/ mice
(Sassi et al., 2012). Therefore, a greater understanding of the physio-
logical and pathological role(s) of MRPs in the regulation of cyclic
nucleotide efflux is needed if these transporters are to be established
as key players in terminating cGMP signalling and, consequently, as
potential target in promoting the cytoprotective functions of cGMP
for therapeutic benefit in cardiovascular disease.
Herein, in order to establish (patho)physiological role(s) for MRPs
in regulating cGMP efflux and signal termination in the cardiovascular
system, we have used functional pharmacological characterisation of
vascular smooth muscle proliferation, isolated blood vessel reactivity,
acute BP responses and an experimental model of heart failure in the
absence of presence of MRP inhibition.
2 | METHODS
2.1 | Materials
ANP (Cambridge Bioscience, Cambridge, UK), spermine-NONOate
(Sper-NO; Sigma Aldrich, Poole, UK), MK571 (MK; Sigma Aldrich),
isoprenaline (Iso; Sigma Aldrich), phenylephrine (Sigma Aldrich) and
ACh (Sigma Aldrich) were dissolved in deionised, distilled water
(ddH2O). For acute BP studies, sodium nitroprusside (SNP; Sigma
Aldrich), diethylenetriamine/NO adduct (Deta-NO; Sigma Aldrich) and
MK571 were dissolved in saline (0.9%; Baxter, Newbury, UK). For
telemetry studies, MK571 was dissolved in the drinking water.
Probenecid (Sigma Aldrich) and ODQ (1H-[1,2,4]oxadiazolo[4,3,-a]
quinoxalin-1-one; synthesised in-house) were dissolved in DMSO
(Sigma Aldrich), and identical DMSO concentrations added to control
cells/tissues.
Animal studies are reported in compliance with the ARRIVE
guidelines (Percie du Sert et al., 2020) and with the recommendations
made by the British Journal of Pharmacology (Lilley et al., 2020). All
animal procedures were conducted in accordance with the UK Home
Office Animals (Scientific Procedures) Act of 1986 and were approved
by a local animal welfare and ethical review board. Animals were
housed in a temperature-controlled environment with a 12-h
light–dark cycle. Food and water were accessible ad libitum. For
in vivo experimentation, animals were randomly assigned to interven-
tions and the experimenter was blinded to treatment. For cell- and
tissue-based studies, interventions were randomly assigned but the
experimenter was not blinded to treatment.
2.2 | Cell proliferation
Human coronary artery smooth muscle cells (hCASMCs; Passages
5–7; Lonza, Basel, Switzerland) were seeded onto six-well plates at a
density of 30,000 cells per well. Cells were initially grown for 24 h in
routine cell culture medium (Smooth Muscle Growth Medium-2;
Lonza) with SmGM™-2 BulletKit containing FBS (5%), human EGF
insulin, human fibroblastic growth factor and gentamicin/
amphotericin B (proprietary concentrations). Subsequently, the cells
were serum starved (FBS: 0.5%) for 48 h to synchronise cell cycles.
Cells were then incubated in medium containing 5% serum in the
presence of vehicle (sterile ddH2O) or pharmacological treatment, and
cells (stained with trypan blue diluted 1:1 to identify dead cells) coun-
ted at 0-, 24-, 48-, 72- and 96-h intervals using a haemocytometer.
Individual plates were set up with the same treatments, in duplicate
wells, one for each time point. Cells seeded at an initial density of
30,000 cells per well grew at an exponential rate under control condi-
tions without becoming confluent (Figure 1). This proliferative profile
was explored in the absence and presence of MK571 (30 nM to
30 μM), ANP (100 nM), the NO donor diethylenetriamine-NONOate
(Deta-NO; 10 μM) or combinations thereof.
2.3 | cGMP assay
Intracellular and extracellular cGMP concentrations were measured by
ELISA (GE Healthcare, Hatfield, UK) following 24 h of treatment in
the same cells used for the proliferation assays described above. Each
well was treated with the non-selective PDE inhibitor IBMX (100 μM;
Sigma Aldrich) for 30 min prior to cell and supernatant harvest to
prevent breakdown of cGMP during cell processing. Cell pellet (for
intracellular cGMP) and supernatant (for extracellular cGMP) were
frozen and stored at 80C until use. In vivo cGMP measurements
were determined using an identical ELISA (as above), determined in
whole heart homogenates (for intracellular cGMP) and plasma (for
extracellular cGMP), treated with IBMX (100 μM; as above) and
frozen and stored at 80C until use. cAMP concentrations were
also evaluated in heart homogenates and plasma by ELISA
(GE Healthcare). Extraction of cyclic nucleotides and ELISA were
conducted as the per manufacturer's instructions.
2.4 | Organ bath pharmacology
Mice (C57/BL6; male and female; 20–30 g) were killed by cervical
dislocation. The thoracic aortae were carefully removed, cleaned of
connective tissue and cut into three to four ring segments of approxi-
mately 4 mm in length. Aortic rings were mounted in 10-ml organ
baths containing Krebs-bicarbonate buffer (composition [mM]: Na+




2 1.2; D-glucose 11) and gassed with carbogen (95% O2/5% CO2;
British Oxygen Company [BOC], Guildford, UK). Tension was initially
set at 0.3 g and reset at intervals following an equilibration period of
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approximately 1 h during which time fresh Krebs-bicarbonate buffer
was replaced every 15 min. After equilibration, the rings were primed
with three separate additions of KCl (48 mM; Sigma Aldrich), at each
addition maximum tension was observed (3 min) before being washed
out by the addition of fresh Krebs-bicarbonate buffer at 10 min inter-
vals for a total of 30 min. Cumulative concentrations of the
α-adrenoceptor agonist phenylephrine (1 nM to 3 μM) were then
added until a maximum contraction was observed. Another washout
period was performed before vessels were contracted to an EC80 con-
centration of phenylephrine. Once this response had stabilised, a sin-
gle addition of the endothelium-dependent dilator ACh (1 μM) was
added to the bath to assess the integrity of the endothelium. If the
contractions to phenylephrine were not maintained, or ACh produced
relaxations of less than 50% of the phenylephrine-tone, tissues were
discarded. After another wash period, the vessels were again con-
tracted with phenylephrine (EC80) and cumulative concentration
response curves to MK571 (100 nM to 30 μM) or probenecid (1 μM
to 1 mM) constructed; responses to MK571 were also studied in the
presence of the NO-sensitive GC (GC-1/2) antagonist ODQ (5 μM) or
the G-kinase inhibitor KT5823 (2 μM). In further studies, tissues were
pre-contracted with an EC80 concentration of phenylephrine and then
concentration–response relationships for ACh (1 nM to 3 μM), ANP
(1 pM to 300 nM), the NO donor Sper-NO (1 nM to 30 μM) or the
β-adrenoceptor agonist isoprenaline (300 pM to 300 nM) determined
in the absence and presence of a subthreshold concentration (3 μM;
15 min pre-incubation) of MK571.
2.5 | Acute BP measurement in
anaesthetised mice
Mice (C57/BL6; male and female; 20–30 g) were anaesthetised
with 1.5% isoflurane (Abbott Laboratories Ltd, Queenborough, UK)
in O2 and placed supine on a thermostatically controlled heating
blanket (37.0C ± 0.5C). To measure BP, the left common carotid
artery was isolated and a fluid-filled (heparin; 100 Uml1 diluted in
0.9% saline), 0.28-mm internal diameter cannula (Critchley Electrical
Products Pty Ltd, Castle Hill, Australia) introduced into the artery.
BP was measured using an in-line P23 XL transducer (Viggo-
Spectramed, California, USA) and PowerLab system, calibrated
beforehand and recorded using LabChart (ADInstruments, Castle
Hill, Australia). The jugular vein was cannulated for drug adminis-
tration. The arterial cannula was flushed once with heparinised
saline (heparin; 100 Uml1 diluted in 0.9% saline). After a
minimum 10-min equilibration or until continuous stable pressure
was observed, mice were given a weight adjusted (1 μl/1 g of body
F IGURE 1 Proliferation (a–c) and intracellular:extracellular cGMP ratio (d–f) in human coronary artery smooth muscle cells in the absence
(control) or presence of MK571 (30 nM to 30 μM; a), Deta-NONOate (Deta-NO; 30 μM; b) or atrial natriuretic peptide (ANP; 100 nM; c), or
combination of Deta-NO or ANP (at the same concentrations) with MK571 (30 nM; b, c). Data are shown as mean ± SEM. Statistical analysis by
one-way ANOVA with Šídák post hoc test. *P <0.05 (adjusted for multiplicity)
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weight) i.v. bolus injection of MK571 (0.001–3 mgkg1). The
3 mgkg1 dose was chosen as subthreshold. Subsequently BP was
measured following i.v. bolus administration of the NO donor
SNP (1–10 μgkg1) or ANP (1–100 μgkg1) in the absence and
presence of MK571 (3 mgkg1; pre-incubated for 30 min).
2.6 | Chronic BP measurement in conscious
telemeterised mice
Mice (C57/BL6; male and female; 20–30 g) were implanted with a
DSI PhysioTel® HD-X11 telemetry probe (Data Sciences International,
Minneapolis, USA). Each probe was cleaned and sterilised according
to the manufacturer's guidelines. Mice were anaesthetised with 5%
isoflurane in O2 and anaesthesia was maintained using 1.5%–2% iso-
flurane in O2 with body temperature maintained at 37C. The left
common carotid artery was exposed, isolated and cleaned of any sur-
rounding tissue. A small incision was made in the carotid, and the
catheter inserted whilst submerged in saline to ensure no bubble form
inside the catheter tip. The tip of the catheter was placed into the
aortic arch, securely fastened and the transmitter body placed s.c. on
the right flank. The incision was stitched and each animal
received post-operative analgesia consisting of 0.3-μg Vetergesic®
(buprenorphine; Abbott Laboratories Ltd) in 0.5-ml saline (s.c.).
Animals were left to recover for a minimum of 7 days, after which
haemodynamic recordings were taken for 64 h over the weekend to
minimise noise disturbance. Mean arterial BP (MABP), heart rate
(HR) and activity were recorded for 2 min at 15-min intervals using
Dataquest Art Acquisition System (Data Sciences International). Base-
line haemodynamic measurements were taken 1 week before dosing.
The daily drinking water consumption was measured each day, and,
where appropriate, water bottles were replaced with bottles
containing MK571 at a concentration that entailed each mouse
received 25 mgkg1day1 (based on a mean consumption of
4 mlmouse1day1). A 24-h time period was used for analysis
starting from 1 pm Saturday and ending 1 pm Sunday (12 h light/
dark), with dosing commencing 24 h before the start of this time
period.
2.7 | Pressure overload-induced heart failure
Abdominal aortic constriction (AAC) was performed at the suprarenal
level to induce pressure overload. Mice (C57/BL6; male and female;
20–30 g) were anaesthetised (1.5% isoflurane in O2) and the analgesic
buprenorphine was administered (0.1 mgkg1; i.m.; Centeur, UK).
Mice were placed under an operating microscope in the supine
position with body temperature maintained at 37C. An incision was
made in the abdominal cavity and the abdominal aorta was separated
from the surrounding tissue at the suprarenal level by moderate dis-
section. Aortic constriction was performed by tying a 4–0 surgical
thread against a 25-gauge needle between the superior mesenteric
and renal arteries. This produces a 30% constriction of the luminal
diameter. For sham operations, the 4–0 surgical thread was passed
under the aorta and removed without tying it against the needle. To
close internal and external incisions, 6.0 absorbable and non-
absorbable sutures were used, respectively, and local anaesthetic
(lidocaine hydrochloride; 2.0% w/v; Dechra, UK) was administered.
Mice were monitored regularly for 3 days post-surgery. MK571
(25 mgkg1day1) was delivered in the drinking water (changed
every other day, based on average water consumption) starting at
Day 21 following abdominal aortic constriction and maintained
throughout the remaining 3 weeks of study.
To track changes in cardiac morphology and function in vivo,
M-mode echocardiograms were obtained from anaesthetised mice
at baseline, 3 and 6 weeks post-abdominal aortic constriction using
a VisualSonics Vevo 3100 echocardiographic system and a 40-MHz
transducer. Mice were anaesthetised (1.5% isoflurane in O2) and
placed in the supine position with body temperature maintained at
37C. LV internal diameter (LVID) at diastole (d) and systole
(s) was measured from short-axis M-mode images. LV ejection
fraction (LVEF, %) was calculated as follows:- LVEF (%) =
[(LVIDd)3  (LVIDs)3]/(LVIDd)3  100. Values were averaged from 3
beats. ECG, HR, and respiration rate were also recorded. Animals
were closely monitored durign recovery from anaesthesia and, if
necessary, provided with extra supportive care (e.g. thermoregula-
tory support).
2.8 | Histology, staining and imaging
For murine studies, the isolated left ventricles were cut transversely
below the mitral valves, fixed in 10% formalin for 24 h and then
stored in 70% ethanol before embedding in paraffin wax and section-
ing (6-μm transverse sections). Human heart samples from ‘healthy’
(non-failing) control patients and those with heart failure
(i.e. ischaemic cardiomyopathy or dilated cardiomyopathy) were
obtained under ethical approval from the Institutional Review Boards
at the University of Pennsylvania and the Gift-of-Life Donor Program
(Pennsylvania, USA), and the kind gift of Dr. K. Margulies and
Dr. K Bedi.
2.9 | Picrosirius red staining
Tissue slides were dewaxed, rehydrated and stained with Picrosirius
Red (0.1% w/v) to visualise collagen fibres in the heart. Images were
obtained using a Nanozoomer S210 Slide Scanner (40 objective,
Hamamatsu, Japan) and analysed by threshold analysis using ImageJ
(National Institutes of Health).
2.10 | Quantitative RT-PCR and immunoblotting
Left ventricles were snap frozen, broken down using a pestle and mor-
tar and then homogenised using QIAshredder technology. RNA was
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extracted using a Fibrosis Tissue extraction kit (as above; Qiagen) and
quantified using a NanoDrop spectrophotometer (ThermoFisher
Scientific, MA, USA). One microgram of RNA was converted to cDNA
by reverse transcription (High Capacity RNA-to-cDNA Kit; Applied
Biosystems, Life Technologies Ltd, UK). Specific primers for hypertro-
phic or fibrotic markers (detailed in Table 1) and housekeeping gene
ribosomal protein L19 (RPL19) were added to cDNA template and
SyBr Green quantitative PCR mix (PowerUp™ SYBR Green master
mix, Fisher Scientific, UK). Ten nanograms of cDNA from each sample
was amplified using quantitative real-time PCR over 45 cycles, as per
the manufacturer's instructions in the thermal cycler (CFX96 Connect
Realtime System, Bio-Rad, UK). Samples were subjected to melting
curve analysis to confirm amplification specificity. mRNA expression
was analysed by expressing the cycle threshold (Ct) value as 2ΔΔCt,
relative to the levels of RPL19, and further normalised as a fold change
to control.
Standard SDS-PAGE protocols were employed to identify MRP4
protein expression using anti-MRP4 (1:500, ab15602, Abcam) and
anti-vasodilator stimulated phosphoprotein (total VASP; 1:1000,
ab205952, Abcam), anti-phospho-VASP157(1:1000, clone 3111, Cell
Signaling) and anti-phospho-VASP239 (1:1000, clone 3114, Cell Signal-
ing) used as an index of myocardial cGMP/G-kinase signalling activity
(Butt et al., 1994). GAPDH (1:50,000; ThermoFisher Scientific) was
used as loading control. The Immuno-related procedures used comply
with the recommendations made by the British Journal of Pharmacol-
ogy (Alexander et al., 2018).
2.11 | Statistical analyses
The data and statistical analysis comply with the recommendations on
experimental design and analysis in pharmacology (Curtis et al., 2018).
All data are reported as mean ± SEM, where n denotes the number of
mice used in each group. Statistical analyses were conducted using
GraphPad Prism (Version 8; GraphPad Software, USA). For the com-
parison of two groups of data, a two-tailed, unpaired Student's t-test
was used. When comparing three or more groups of data, either a
one-way or two-way ANOVA followed by a Šidák multiple compari-
sons test was used with adjustment for multiplicity. A P-value < 0.05
was considered statistically significant, and the P-values presented in
each figure indicate all comparisons undertaken. Post hoc tests were
conducted only if F in ANOVA achieved P < 0.05. Sample sizes sub-
jected to statistical analysis were at least five animals per group (n =
5, where n is the number of independent values).
2.12 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPS Guide to PHARMACOL-
OGY http://www.guidetopharmacology.org and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20
(Alexander et al., 2019).
3 | RESULTS
3.1 | Smooth muscle cell proliferation
MK571 (30 nM to 30 μM) concentration-dependently inhibited
human coronary artery smooth muscle cell (hCASMC) proliferation
compared with control (Figure 1a); 30-μM MK571 completely
arrested cell growth but also changed cell morphology and lowered
viability. Based on these data, a subthreshold concentration of
MK571 (30 nM) was selected to study effects of MRP inhibition on
the anti-proliferative effects of NO and ANP. Deta-NO (10 μM) and
ANP (100 nM) were chosen due to their ability to elicit submaximal
inhibition of human VSMC proliferation (Bubb et al., 2014). Deta-NO
and ANP alone did not significantly alter hCASMC proliferation,
although a tendency for both to reduce mean fold change in cell num-
ber was observed (Figure 1b,c). However, when the subthreshold con-
centration of MK571 (30 nM) was combined with either Deta-NO or
ANP, a significantly enhanced inhibitory effect on hCASMC prolifera-
tion was observed compared with control (Figure 1b,c). Moreover,
MK571 combined with ANP significantly inhibited hCASMC growth
compared with ANP alone (Figure 1c), although a similar potentiation
was not seen with MK571 plus Deta-NO (Figure 1b).
TABLE 1 Primer sequences for RT-PCR analyses
Target Sequence (50 ! 30)
Mouse αSMA Forward: ACTACTGCCGAGCGTGA
Reverse: ATAGGTGGTTTCGTGGATGC
Mouse ANP Forward: GGATTTCAAGAACCTGCTAGACC
Reverse: GCAGAGCCCTCAGTTTGCT
Mouse Col1α1 Forward: TCTGACTGGAAGAGCGGAGAG
Reverse: AGACGGCTGAGTAGGGAACA
Mouse Col1α2 Forward: TGGATACGCGGACTCTGTTG
Reverse: CCCTTTCGTACTGATCCCGATT
Mouse Col3α1 Forward: GGGAGGAATGGGTGGCTATC
Reverse: CTGGGCCTTTGATACCTGGA
Mouse fibronectin Forward: CCGGTGGCTGTCAGTCAGA
Reverse: CCGTTCCCACTGCTGATTTATC
Mouse MMP-2 Forward: TGTCGCCCCTAAAACAGACA
Reverse: CAGGTGTGTAACCAATGATCCTGT
Mouse MRP4 Forward: CCGTCCTTTTTGGCATAGCG
Reverse: CGAGGAGCAACGTCTGGATG
Human MRP4 Forward: CCCGTGTACCAGGAGGTGAA
Reverse: GGGATTGAGCCACCAGAAGAA
Mouse MRP5 Forward: CCGTGGAGAGGATCAACCAC
Reverse: CCAAAGAGGACTTCCCTGACC






Mouse SERCA2a Forward: TGGAACCTTTGCCGCTCATTT
Reverse: CAGAGGCTGGTAGATGTGTT
Mouse TGF-β1 Forward: TCAGACATTCGGGAAGCAGT
Reverse: GCCCTGTATTCCGTCTCCTTG
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3.2 | Effect of multidrug resistance protein (MRP)
inhibition on intracellular and extracellular cGMP
concentrations
To investigate whether MRP inhibition augments VSMC growth
through effects on cGMP dynamics/transport, intracellular and
extracellular cGMP concentrations were measured in hCASMC at
the 24-h time point, under identical conditions employed for the
proliferation assays described above. Human CASMC grown under
control conditions showed an essentially equal intracellular and
extracellular level of cGMP (Figure 1d). In hCASMCs treated with
MK571 (30 nM to 3 μM), the intracellular and extracellular cGMP
concentrations did not differ significantly from control (Figure 1d).
Following 24-h treatment with Deta-NO (10 μM) in the absence or
presence of a subthreshold concentration of MK571 (30 nM), the
intracellular:extracellular cGMP ratio did not significantly change,
although there was a tendency for this to increase in the presence
of Deta-NO (Figure 1e). However, 24-h treatment with ANP
(100 nM) produced a clear reduction in the intracellular:extracellular
cGMP ratio that was significantly restored in the presence of
MK571 (Figure 1f; absolute cGMP levels for all conditions are
depicted in Figure S1). These findings suggest that efflux of cGMP
through MRP4/MRP5 (i.e. MK571-inhibitable MRPs) regulates the
cellular response of hCASMC to NO donors and ANP, but that
activation of the membrane-spanning GC-A by ANP is subject to
significant cGMP efflux that is sensitive to MRP blockade.
3.3 | Effect of MRP inhibition on vascular
reactivity
To determine if cell-based findings were mirrored in a functional phar-
macological fashion in whole blood vessels, studies were performed
on mouse thoracic aorta. Here, the structurally-distinct MRP inhibitors
MK571 (100 nM to 30 μM) and probenecid (1 μM to 1 mM) produced
concentration-dependent relaxations of phenylephrine-induced tone,
with the highest concentrations of each resulting in 100% relaxation
(Figure 2a,b). In addition, the concentration-dependent relaxations to
MK571 (100 nM to 30 μM) were significantly shifted to the right in
the presence of the NO-sensitive GC inhibitor ODQ (5 μM) and the
G-kinase inhibitor KT5823 (2 μM; Figure 2a) confirming the cGMP
dependency of these relaxations.
A subthreshold concentration of MK571 (3 μM) was chosen to
assess the effects of MRP inhibition on vasorelaxant responses. The
endothelium-dependent vasorelaxant ACh exerted concentration-
dependent relaxations of phenylephrine pre-contracted mouse aorta
that were not significantly different in the presence of MK571
(Table 2 and Figure 2c). The NO donor, Sper-NO, ANP, CNP and the
β-adrenoceptor agonist isoprenaline all induced concentration-
dependent relaxations of phenylephrine tone that were sensitive to
MRP inhibition. The greatest effect of MRP inhibition on cGMP-
driven responses was observed on vasorelaxation to ANP; MK571
significantly increased the potency of both vasodilators by approxi-
mately fourfold (Table 2 and Figure 2d). Echoing the observations
F IGURE 2 Vasorelaxant responses to MK571 (100 nM to 30 μM; a) and probenecid (1 μM to 10 mM; b) alone or MK571 in the presence of
the GC-1/2 inhibitor, ODQ (5 μM) or G-kinase inhibitor KT5823 (2 μM; a), and to ACh (1 nM to 3 μM; c), atrial natriuretic peptide (ANP; 0.01–
100 nM; d), spermine-NONOate (Sper-NO; 1 nM to 30 μM; e) and isoprenaline (Iso; 1 nM to 3 μM; f ) in the absence and presence of MK571
(3 μM) in mouse isolated aorta. Data are shown as mean ± SEM. Statistical analysis by two-way ANOVA across the entire concentration–
response curve. *P <0.05 (adjusted for multiplicity)
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from the cell-based studies (above), the potency of Sper-NO was
enhanced to a lesser degree when combined with MK571 (Table 2
and Figure 2e). Finally, MK571 significantly increased the potency of
isoprenaline (Table 2 and Figure 2f), confirming a dual action on
cGMP- and cAMP-mediated vasorelaxant responses.
3.4 | Effect of MRP inhibition on acute
changes in BP
As a whole, in vitro observations suggest that MRP4 and/or MRP5
play a key role in regulating cGMP-driven responses in the vasculature
and that this phenomenon is more important in with respect to
natriuretic peptide/particulate GC signalling compared with
NO-sensitive GC/cGMP processes. To determine if such an influence
was also functionally apparent in vivo, the effect of MRP inhibition
on NO- and ANP-induced acute changes in BP was explored in
anaesthetised mice.
Administration of MK571 at doses ranging from 0.1 μgkg1 to
3 mgkg1 caused little or no change in MABP or HR (Figure 3a,b).
Accordingly, the highest dose (3 mgkg1) of MK571 was used in sub-
sequent experiments to assess the effect of MRP inhibition on
haemodynamic responses to NO and ANP. The NO donor SNP (1, 3
and 10 μgkg1; i.v. bolus) and ANP (1, 10 and 100 μgkg1; i.v. bolus)
were chosen due to their ability to elicit dose-dependent reductions
in MABP (Madhani et al., 2006). SNP produced a dose-dependent
decrease in MABP, which was not significantly altered when com-
bined with MK571 (Figure 3c). SNP also elicited a dose-dependent
increase in HR, but this was not changed by MK571 (Figure 3d). ANP
also produced dose-dependent decreases in MABP, however in this
TABLE 2 Absolute and fold change in EC50 values for vasorelaxant responses to ACh, atrial natriuretic peptide (ANP), spermine-NONOate
(Sper-NO) and isoprenaline (Iso) in mouse isolated aorta in the absence and presence of the multidrug resistance protein (MRP) inhibitor MK571
(3 μM)
Log EC50 (M)
Fold shift P valueControl + MK571 (3 μM)
ACh 7.206 ± 0.103 7.296 ± 0.111 1.23 > 0.05
ANP 8.570 ± 0.089 9.175 ± 0.093 4.03 *< 0.05
Sper-NO 6.264 ± 0.093 6.612 ± 0.057 2.23 *< 0.05
Iso 6.441 ± 0.120 7.056 ± 0.109 4.12 *< 0.05
F IGURE 3 Changes in mean arterial BP (MABP; a, c, e) and heart rate (b, d, f) in anaesthetised mice following bolus doses of MK571
(0.1 μgkg1 to 3 mgkg1, i.v.; a, b), or bolus doses of sodium nitroprusside (SNP; 1–10 mgkg1, i.v.; c, d) or atrial natriuretic peptide (ANP;
1–10 μgkg1, i.v.; e, f) in the absence and presence of MK571 (3 mgkg1). Data are shown as mean ± SEM. Statistical analysis by two-way
ANOVA across the entire dose–response curve. *P <0.05 (adjusted for multiplicity)
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case, the hypotensive response to ANP was significantly enhanced in
the presence of MK571 (Figure 3e). The effects of ANP on HR were
not significantly different following MK571 administration (Figure 3f).
These data imply that MRP inhibition has a preferential ability to
promote ANP/GC-A/cGMP signalling in the vasculature compared
with NO/GC-1/cGMP pathway, but that basally, MRP inhibition does
not significantly alter cGMP-driven vasodilation, perhaps arguing that
in healthy animals intracellular levels of cGMP are not sufficient to be
affected by MRP-driven efflux.
3.5 | Effect of MRP inhibition on chronic changes
in blood pressure
In vivo studies in anaesthetised mice suggested that MRP inhibition
acutely enhances the hypotensive activity of ANP, but not NO,
substantiating earlier in vitro observations. Investigations were
therefore undertaken to establish whether MK571 was able to modu-
late BP in conscious telemetered mice in vivo over a 24-h period. Mice
had a normal circadian rhythm with respect to MABP, HR and activity
during the 24-h time period (Figure 4a–f). Notably, there were no
significant differences in MABP, HR or activity over the 24-h period
(or during either the 12-h light or dark phase) in the absence or
presence of MK571 (Figure 4a–f). These findings are in accord with
the acute BP measurements in that at rest (i.e. healthy mice) MRP
inhibition does not play a significant role in vascular cGMP-dependent
signalling.
3.6 | Effect of MK571 on experimental heart
failure
Because MRP inhibition appeared to preferentially augment ANP-
elicited cGMP responses in the vasculature in vitro and in vivo, it
was hypothesised that cGMP efflux via MRPs might play a key role
in cGMP-dependent signalling in vivo in a setting of high back-
ground natriuretic peptide levels. Thus, a well-established model of
pressure overload-induced heat failure (i.e. abdominal aortic con-
striction; Moyes et al., 2020) was employed as this condition is
associated with significant elevated circulating natriuretic peptide
concentrations in rodents and patients (Potter et al., 2009; Wang
et al., 2004; Wei et al., 1993).
Pressure overload produced the expected increase in LV wall
thickness and LV dilatation, and reduced contractility (i.e. fractional
shortening and ejection fraction), characteristics of an heart failure
phenotype (although this did not result in a significant reduction in
cardiac output or stroke volume, Figures 5 and 6). Remarkably, the
vast majority of these indices of disease severity were reversed in
the presence of MK571, manifesting as both improved cardiac mor-
phology and enhanced myocardial contractility (Figure 5a–f). This was
mirrored by qPCR analysis of the cardiac expression of pro-
hypertrophic and pro-fibrotic markers which were increased in
response to pressure overload, with the exception of SERCA2, which
was decreased in line with a previous report (Nagai et al., 1989).
These effects were reversed in the presence of MK571 (Figure S2).
The anti-fibrotic actions of MRP inhibition were confirmed by assess-
ment of collagen deposition (Figure S3). Importantly, MK571 did not
significantly reduce MABP following abdominal aortic constriction,
indicating that the beneficial actions of MRP inhibition are not due to
indirect effects on BP.
3.7 | Expression of MRP4 and MRP5 in heart
failure
Molecular analysis revealed contrasting effects of pressure overload
on MRP subtype expression. MRP4 mRNA levels trended towards a
reduction in experimental heart failure, and this was corroborated at
the protein level (Figure S4). However, expression of MRP5 mRNA
was significantly increased in response to abdominal aortic constric-
tion (Figure S4). These changes were largely mirrored in tissue from
patients with heart failure with the exception of MRP4 expression in
ischaemic patients, suggesting that this mouse model closely mimics
the human medical condition (Figure S4).
3.8 | Effect of MK571 on cGMP levels in vivo
following pressure overload
To evaluate whether the advantageous outcome associated with
MK571 administration in experimental heart failure was dependent
on promoting tissue cGMP levels, measurements of cardiac and
plasma cyclic nucleotides were conducted. cAMP levels in the heart
and plasma exhibited little or no change following abdominal aortic
constriction in the absence and presence of MK571 (Figure 7a–c). In
contrast, abdominal aortic constriction tended to cause an increase
in cardiac cGMP levels and markedly elevated circulating cGMP levels,
perhaps indicative of cardiac production of cGMP but significant cel-
lular efflux (Figure 7c–e). Intriguingly, in the presence of MK571, car-
diac cGMP levels were maintained at levels commensurate with
abdominal aortic constriction alone, but plasma cGMP concentrations
were significantly reduced (Figure 7c–e), intimating a positive shift in
the intracellular:extracellular cGMP balance. The functional impor-
tance of cGMP in mediating the beneficial effects of MK571 in vivo
was further corroborated by studies showing that phosphorylation of
VASP at Ser157 and Ser239 was significantly increased in hearts from
animals exposed to abdominal aortic constriction treated with MK571
versus mice with abdominal aortic constriction alone (Figure S5).
4 | DISCUSSION
Cellular efflux has been postulated to contribute to
compartmentalisation of cGMP signalling. This has been postulated
based on cell- and tissue-based systems and understood to involve, at
least in part, MRP4 and/or MRP5, although gap junctions may also
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F IGURE 4 Twenty-four hours (a–c) and mean (d–f) radiotelemetry evaluation of mean arterial BP (MABP; a, d), heart rate (HR; b, e) and
activity (c, f) in conscious mice in the absence and presence of MK571 (25 mgkg1day1). Data are shown as mean ± SEM (error bars omitted
for clarity in a–c). Statistical analysis by two-way ANOVA across all time points. *P <0.05 (adjusted for multiplicity)
F IGURE 5 Fractional shortening (FS; a), left ventricular ejection fraction (LVEF; b), left ventricular internal diameter at diastole (LVIDd; c), left
ventricular posterior wall diameter at diastole (LVPWDd; d), cardiac output (CO; e) and heart rate (HR; f) in sham mice and animals undergoing
abdominal aortic constriction (AAC; 6 weeks) in the absence and presence of MK571 (25 mgkg1day1; p.o.). Data are shown as mean ± SEM.
Statistical analysis by one-way ANOVA with Šídák post hoc test. *P <0.05 (adjusted for multiplicity)
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fulfil this remit, Bevans et al., 1998. However, there is a paucity of
information regarding the physiological and pathological role(s)
of extracellular transport of cGMP in governing vascular and cardiac
function. Herein, we establish that multidrug resistance proteins
(MRPs) play an overt role terminating cGMP signalling in blood vessels
and the heart, regulating vascular smooth muscle proliferation, vessel
reactivity, BP and the severity of cardiac damage in experimental
heart failure. Interestingly, the sphere of action of MRPs appears to
be directed towards membrane-localised natriuretic peptide-driven
cGMP synthesis, with a lesser influence on NO-sensitive GC-
generated cGMP pathways. These observations help define a central
role for cGMP efflux via MRPs as a mechanism to turn off cGMP-
dependent response and pharmacological inhibitors of this process
may hold promise in the treatment of cardiovascular disease akin to
existing modulators of cGMP signalling (i.e. PDE inhibitors and neutral
endopeptidase [NEP] inhibitors).
To elucidate potential functional role(s) of MRPs in the cGMP-
mediated inhibition of hCASMC proliferation, the MRP4/MRP5
inhibitor MK571 (Chen et al., 2002; Jedlitschky et al., 2012; Reid
et al., 2003) was employed. MK571 produced a concentration-
dependent reduction in hCASMC growth in the absence of exoge-
nous cGMP-elevating agents. Because healthy VSMCs do not
express NO synthase or natriuretic peptides, it is likely this innate
anti-proliferative action of MK571 is a consequence of reducing
export of basal cGMP production by the inherent GCs, a phenome-
non well established for the NO-sensitive enzymes, but less so for
the particulate isozymes (Potter & Garbers, 1992; Wolin et al., 1982).
Moreover, a concentration of MK571 that did not significantly
reduce proliferation per se augmented the anti-proliferative effects of
subthreshold concentrations of both NO and ANP. Such findings
imply that cellular efflux is a key mechanism regulating the anti-
proliferative effects of cGMP, regardless of the synthesising GC
(i.e. NO or natriuretic peptide sensitive). This concept was corrobo-
rated, to a certain degree, by measurements of intracellular and
extracellular cGMP levels. Here, MRP inhibition alone tended to
increase the intracellular:extracellular cGMP ratio, indicative of a
reduction in transport out of the cell. However, the low basal cGMP
concentrations entailed that such changes were modest at best. The
NO donor, Deta-NO, tended to increase the mean intracellular cGMP
concentrations, but MK571 was unable to increase this further. In
contrast, the effect of MRP inhibition on ANP-mediated rises in
cGMP was more clear cut. Interestingly, addition of ANP actually
reduced the intracellular:extracellular cGMP ratio, driven by a subtle
rise in intracellular levels but a dramatic increase in extracellular
cGMP concentrations. In addition, in the presence of MK571, this
balance was restored to a basal phenotype in which intracellular
cGMP was significantly greater than extracellular cGMP. This pro-
nounced effect of MRP inhibition on ANP responses fits with the
particulate nature of this cognate GC, as synthesis of cGMP in the
juxtamembrane region by GC-A should be in proximity to MRPs and
thereby more overtly influenced by cGMP efflux. The lack of effect
of MK571 and NO donor alone, or combination of the two, on cGMP
F IGURE 6 Mean arterial BP
(MABP; a), heart weight to tibia
length ratio (HW/TL; b), left
ventricular weight to tibia length
ratio (LVW/TL; c) and left
ventricular mass (LV mass; d) in
sham mice and animals
undergoing abdominal aortic
constriction (AAC; 6 weeks) in the
absence and presence of MK571
(25 mgkg1day1; p.o.). Data are
shown as mean ± SEM. Statistical
analysis by one-way ANOVA with
Šídák post hoc test. *P <0.05
(adjusted for multiplicity)
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levels suggest that the NO-sensitive GC generates cGMP in a more
diffuse, cytoplasmic region that is less sensitive to efflux via MRPs.
These observations confirm and extend previous reports indicating
that cGMP extrusion plays a critical role in terminating signalling in
vascular tissue (Krawutschke et al., 2015), although herein it is dem-
onstrated that natriuretic peptide-stimulated cGMP production is
more susceptible to MRP-mediated regulation. Published work also
supports the notion that cGMP produced by the membrane-spanning
GCs is maintained in proximity to the membrane by PDE2 and PDE3,
thereby accentuating the consequences of cellular efflux (Castro
et al., 2006; Fischmeister et al., 2006; Krawutschke et al., 2015).
Echoing findings in cell-based experiments, MK571 and the struc-
turally distinct MRP inhibitor probenecid (Hamet et al., 1989) elicited
concentration-dependent relaxations of mouse aorta. Again, the abil-
ity of MRP inhibitors per se to relax vessels probably reflects intrinsic
turnover of cGMP production and turnover as a result of NO produc-
tion in the endothelium and GC-1/2 activity in the smooth muscle.
This thesis is supported by inhibition of MK571-induced
vasorelaxation by the NO-sensitive GC inhibitor, ODQ and the
G-kinase inhibitor KT5823. In further studies, a subthreshold concen-
tration of MK571 and probenecid significantly increased the potency
of Sper-NO- and ANP-induced relaxations. Notably however, the
potentiating effect of MRP inhibition was more pronounced against
natriuretic peptide-dependent relaxations, paralleling observations in
isolated hCASMCs. Oddly, MK571 was unable to potentiate
vasorelaxant responses to ACh, which are solely dependent on NO
release from the vascular endothelium in this tissue (Huang
et al., 1995; Madhani et al., 2003; Scotland et al., 2005). Whether this
is a consequence of cGMP signal compartmentalisation within the
vascular smooth muscle remains to be determined. Specifically, that
ACh-dependent NO release stimulates VSMC GC-1/2 but the cGMP
generated is not of sufficient magnitude to be affected by MRPs,
whereas cGMP production stimulated by exogenous NO (i.e. Sper-
NO) is more global, activating the entire GC-1/2 enzyme pool. This
interpretation is supported by previous findings that increasing con-
centrations of ACh do not elevate extracellular cGMP in rat aorta, in
contrast to the NO donor, SNP (Schini et al., 1989). These data imply
that greater cytosolic cGMP is generated by pharmacological concen-
trations of NO, spilling over into the membrane region and resulting in
increased extrusion by MRPs. It should also be noted that the 3 μM
(subthreshold) concentration of MK571 employed in these studies
produced little or no effect on vascular tone per se, whereas higher
concentrations had a significant vasorelaxant activity. However, at
higher concentrations of MK571, it was not possible to maintain pre-
contraction with phenylephrine. Indeed, an arguably larger vascular
effect of MRP inhibition has been shown in murine aorta in response
to the NO donor, S-nitrosoglutathione, using 10 μM MK571
(Krawutschke et al., 2015). Thus, although the increases in potency
observed in Krawutschke et al. and in the present study are relatively
modest, the beneficial effects of MRP inhibitors are almost certainly
underestimates of the maximum attainable outcome, albeit difficult to
dissect because of the inherent vasorelaxant activity of MRP
F IGURE 7 Fold change versus sham in heart (a, d) and plasma (b, e) cAMP or cGMP concentrations, and heart:plasma cAMP (c) or cGMP
(d) ratio in animals undergoing abdominal aortic constriction (AAC; 6 weeks) in the absence and presence of MK571 (25 mgkg1day1; p.o.).
Data are shown as mean ± SEM. Statistical analysis by one-way ANOVA with Šídák post hoc test. *P <0.05 (adjusted for multiplicity)
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inhibitors. Additionally, MK571 is shown to potentiate vasorelaxant
responses to the β-adrenoceptor agonist isoprenaline, to confirm that
MPRs also functionally regulate cAMP signalling in the vasculature
(Sassi et al., 2008).
Can this preferential activity of MRPs to regulate natriuretic
peptide-sensitive GC signalling be explained by subcellular co-
localisation? Currently, there are little or no data defining MRP
protein–protein interactions with membrane-spanning GCs. However,
MRP4 is localised in caveolin-1-enriched membrane fractions in vas-
cular smooth muscle (Sassi et al., 2008) and both GC-A and GC-B co-
localise with caveolins in the cardiovascular system (Chen et al., 2012;
Doyle et al., 1997). In some situations, this phenomenon may also be
of relevant to NO-sensitive GC because of its ability to translocate to
the plasma membrane via the chaperone Hsp90 (Venema et al., 2003).
In addition, a fraction of endogenous GC-1/2 within the heart is found
in caveolin-3-positive caveolae (Tsai et al., 2012). When present in
the caveolae, the enzyme is protected against oxidation that can occur
from vascular injury, which inactivates the catalytic haem domain in
the β subunit. Therefore, the enzyme remains active compared with
its cytosolic counterparts (Tsai et al., 2012). Overall, this demonstrates
that not only can MRP inhibition potentiate particulate GC produced
cGMP but also in disease environments characterised by oxidative
stress, MRP inhibition may also potentiate cGMP generated from
membrane located sGC, amplifying the signal, thus expanding the
therapeutic potential of MRP inhibitors.
The vasorelaxant effect of MK571 per se appears to be an
isolated vessel phenomenon, because MRP inhibition did not signifi-
cantly affect BP in anaesthetised or conscious mice, despite the com-
pound having a relatively long plasma half-life (2–3 h in humans;
Margolskee, 1991) and the dose used (25 mgkg1day1) having
previously been shown to effectively reverse experimental pulmonary
hypertension (Hara et al., 2011). However, MK571 did exhibit a pref-
erence to potentiate GC-A activation as evidenced by significantly
enhanced reductions in BP elicited by acute bolus doses of ANP (but
not NO). This suggests in situations where endogenous circulating
levels of NPs are increased (e.g. heart failure and pulmonary hyperten-
sion) that MRP inhibition will potentiate particulate GC activity, and
the lack of an observable effect of MRP inhibition on MABP, in
healthy mice, may be due to the low basal circulating concentrations
of NPs. This should not be a surprise as the MRP4/, MRP5/ and
MRP4//MRP5/ mice lack an overt basal phenotype, suggesting
that under healthy conditions, MRPs are not essential to vascular
homeostasis (Borst et al., 2007). However, longer term MRP4
deficiency results in cardiac hypertrophy, as observed in aging
MRP4/ mice, which is not apparent in the same strain at 3 months
(Sassi et al., 2012). Thus, in health, this mechanism may not be crucial
to the maintenance of cardiovascular homeostasis in vivo, whereas its
role may be triggered in cardiovascular disease characterised by
enhanced circulating levels of natriuretic peptides (Potter et al., 2006).
To explore the latter hypothesis, the effect of MK571 on experi-
mental heart failure, induced by pressure overload, was investigated.
Abdominal aortic constriction produced significant systolic dysfunc-
tion, LV hypertrophy and LV dilatation (without any overt changes in
cardiac output or HR). Remarkably, the vast majority of these indices
of disease severity, including markers/drivers or hypertrophy and
fibrosis, were reversed by the addition of MK571, demonstrating that
inhibition of cGMP efflux can promote the well-established beneficial
effects of this cyclic nucleotide in heart failure; presumably, based on
the in vitro and in vivo findings described herein, this salutary action of
MK571 is exerted through augmentation of natriuretic peptide/partic-
ulate GC signalling. The effect of MRP inhibition to promote tissue
retention of cGMP was also apparent in this disease setting. Whereas
cAMP levels remained largely unaltered by the pathology or presence
of MK571, cardiac and circulating cGMP concentrations were ele-
vated in response to abdominal aortic constriction. However, follow-
ing MRP inhibition, the cardiac cGMP levels were maintained whereas
the circulating concentrations were reduced considerably, thereby
markedly improving the intracellular:extracellular cGMP ratio. It might
be argued that MK571 did not increase cardiac cGMP above and
beyond that observed in mice following abdominal aortic constriction
alone, but the salutary actions of MRP inhibition in this regard would
inherently lower natriuretic peptide activity, which is proportionate to
disease severity, and therefore preservation of cardiac cGMP likely
reflects a net increase to that expected. Moreover, myocardial VASP
phosphorylation is significantly increased in the setting of pressure
overload in the presence of MK571, intimating that functional
G-kinase activity is promoted by MRP inhibition, an effect established
to be beneficial in models of heart failure (Frantz et al., 2013; Patrucco
et al., 2014).
Exploration of MRP expression in experimental heart failure and
tissue from heart failure patients revealed a reduction in MRP4 levels,
but a contrasting increase in MRP5, the latter matching a previous
report (Dazert et al., 2003). Further investigation will be required to
determine whether MRP4 or MRP5 plays a more important in regulat-
ing cGMP signalling in health and disease and to elucidate whether
these expressional variations represent a host defence mechanism to
promote cGMP signalling (i.e. MRP down-regulation) or potentially a
pathogenic mechanism (i.e. MRP up-regulation). Such changes might
also be argued to have opposing outcomes with respect to cAMP,
because this cyclic nucleotide is predominantly detrimental in heart
failure. Indeed, the cyclic nucleotide transporting specificity of MRP4
and MRP5 remains controversial. MRP4 is considered a predomi-
nantly cAMP transporting protein despite the fact that MRP4 inhibi-
tion results in elevated intracellular cGMP levels (Hara et al., 2011;
Sassi et al., 2008). Indeed, MRP4 has a fivefold lower Km for cGMP
compared with cAMP, suggesting that it may actually have a prefer-
ence for cGMP over cAMP (Chen et al., 2001). However, the Vmax for
cAMP extrusion is approximately twice as high as cGMP, raising the
possibility that at lower cAMP concentrations, MRP4 transports
cGMP, but at higher cAMP concentrations, cAMP extrusion is
favoured. This theory appears to be supported in practice by studies
that show increasing cAMP levels decrease cGMP efflux, presumably
via competition (Hamet et al., 1989; Patel et al., 1995). In fact, it is
possible that this competitive interaction underpins some of the
crosstalk between the cGMP and cAMP systems, which is often
thought to exclusively originate from the activity of PDE2 (cGMP
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stimulated) and PDE3 (cGMP inhibited) (Conti & Beavo, 2007). In con-
trast, MRP5 is commonly accepted as a predominantly cGMP
transporting protein because of its significantly lower Km (180-fold)
and Vmax (20-fold) for cGMP compared with cAMP (Jedlitschky
et al., 2000). In the vasculature, MRP4 and MRP5 are both expressed
on endothelial cells and VSMCs, so in terms of localisation, both
appear to be present to regulate cGMP efflux (Dazert et al., 2003;
Sassi et al., 2008; Xu et al., 2004). Overall, these findings indicate that
MRP4 and MRP5 are capable of regulating vascular homeostasis, with
the inhibition of both proteins likely to elicit an additive, more
advantageous effect. Elucidation of the precise role of each in cardio-
vascular homeostasis will almost certainly necessitate the use of
MRP4/ and MRP5/ mice (Borst et al., 2007) because isozyme-
selective pharmacological inhibitors do not exist. Indeed, a clear
limitation of the present study is the reliance on suboptimal pharma-
cological tools in elucidating the physiological and pathological roles
of MPRs with respect to cGMP transport. Further work using
non-pharmacological means (i.e. in vitro gene knockdown and in vivo
gene deletion) is warranted to substantiate the findings presented
herein and to determine the consequences of altered MR4 and/or
MRP5 expression/activity (including changes brought about by dis-
ease) on intracellular:extracellular cGMP ratios in the heart and vascu-
lature, and the functional corollaries of this. Such investigations might
help explain why observations from this study are at odds with some
previous reports that concluded the majority of the beneficial effects
of MRP inhibitors result from the augmentation of NO/cGMP signal-
ling (Ahmed et al., 2007; Billiar et al., 1992; Patel et al., 1995). One
explanation for this difference lies with the time and concentrations
of the NO-sensitive GC agonist used. Thus, longer term exposure to
supramaximal NO concentrations results in excessive cGMP produc-
tion that spills over in to the juxtamembrane compartment and is sus-
ceptible to MRP extrusion. However, in a more physiological setting,
we conclude that this phenomenon is largely exclusive to the particu-
late cyclase(s), which synthesise cGMP adjacent to the membrane.
In summary, these data support that concept that MRP inhibition
has ability to promote cytoprotective cGMP signalling in the heart and
vasculature, and provide additional evidence verifying the importance
of MRPs in contributing to cGMP compartmentalisation. Since MRP
inhibitors are already in the clinic (i.e. probenecid), repurposing of such
molecules may offer a rapid and inexpensive means by which to
enhance cGMP-targeted agents for cardiovascular diseases such as
heart failure and pulmonary hypertension. Indeed, synergy between
cGMP elevating agents (e.g. PDE and neutral endopeptidase inhibi-
tors) has been well characterised in experimental models of pulmonary
hypertension and patients with the disease (Baliga et al., 2008, 2014;
Hobbs et al., 2019). This gives credence to the idea that combination
of natriuretic peptide elevating agents (e.g. neutral endopeptidase
inhibitors) with MRP inhibitors is also likely to be of supplementary
therapeutic benefit. Furthermore, in the setting of pulmonary hyper-
tension, blockade of both cGMP- and cAMP-transporting MRPs might
also be argued to hold additional promise. However, the ultimate goal
of utilising MRP inhibitors as drugs is fraught with difficulty. The
selectivity of current inhibitors leaves much to be desired (e.g. MK571
blocks lymphotoxin signalling), MRP4/MRP5 are known to transport
a number of key biological molecules (e.g. ADP, ATP,
5-hydroxytryptamine, steroids and eicosanoids) and both transporters
have a widespread distribution, both within and outside the cardiovas-
cular system (Zhou et al., 2008). Thus, despite the promise of MRP
inhibition as an additional mechanism to pharmacologically augment
the cardioprotective and vasoprotective actions of cGMP, far more
refined and targeted interventions will be necessary to harness this
effectively.
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